INO-8875

DRUG2 trials

Sponsors

Inotek Pharmaceuticals Corporation

Conditions

GlaucomaHealthOcular Hypertension

Phase 1

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

CompletedNCT01123785

Inotek Pharmaceuticals CorporationGlaucoma, Ocular Hypertension

Start: 2010-05-31End: 2012-01-31Updated: 2012-10-15

Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers

CompletedNCT01123772

Inotek Pharmaceuticals CorporationHealth

Start: 2010-05-31End: 2011-02-28Updated: 2012-04-30